Multivariable Cox regression analysis for hazard of relapse after the end of induction therapy
| Variable . | Levels . | Hazard ratio (95% CI) . | P . |
|---|---|---|---|
| BMI | Overweight/obese vs normal/underweight | 2.45 (1.00-5.99) | .049 |
| Age at diagnosis | > 40 y vs ≤ 40 y | 1.18 (0.55-2.51) | .67 |
| Sex | Male vs female | 1.98 (0.93-4.23) | .077 |
| PML/RARα | BCR3 vs BCR1-2 | 2.36 (1.11-5.05) | .026 |
| WBC | ≤ 10 × 109/L vs > 10 × 109/L | 2.24 (0.78-6.42) | .13 |
| Hemoglobin | ≤ 10 g/dL vs > 10 g/dL | 2.41 (1.04-5.58) | .040 |
| Platelets | > 40 × 109/L vs ≤ 40 × 109/L | 1.18 (0.55-2.54) | .67 |
| French-American-British subtype | Variant vs typical | 2.65 (0.93-7.58) | .069 |
| ATRA syndrome | Yes vs no | 0.72 (0.27-1.95) | .52 |
| Variable . | Levels . | Hazard ratio (95% CI) . | P . |
|---|---|---|---|
| BMI | Overweight/obese vs normal/underweight | 2.45 (1.00-5.99) | .049 |
| Age at diagnosis | > 40 y vs ≤ 40 y | 1.18 (0.55-2.51) | .67 |
| Sex | Male vs female | 1.98 (0.93-4.23) | .077 |
| PML/RARα | BCR3 vs BCR1-2 | 2.36 (1.11-5.05) | .026 |
| WBC | ≤ 10 × 109/L vs > 10 × 109/L | 2.24 (0.78-6.42) | .13 |
| Hemoglobin | ≤ 10 g/dL vs > 10 g/dL | 2.41 (1.04-5.58) | .040 |
| Platelets | > 40 × 109/L vs ≤ 40 × 109/L | 1.18 (0.55-2.54) | .67 |
| French-American-British subtype | Variant vs typical | 2.65 (0.93-7.58) | .069 |
| ATRA syndrome | Yes vs no | 0.72 (0.27-1.95) | .52 |